Chimeric RSV, immunogenic compositions, and methods of use
AssigneeEmory University
InventorsMartin L. Moore, Christina Rostad
Life of this patent
Estimating the term…
Abstract
This disclosure relates to chimeric respiratory syncytial virus (RSV), live attenuated vaccine and immunogenic compositions, and methods of use. In certain embodiments, the chimeric respiratory syncytial virus has a mutated gene pattern encoding an RSV F protein having M at position 79, R at position 191, K at position 357, and/or Y at position 371.
Claims16
A respiratory syncytial virus (RSV) F protein comprising K at position 357 and Y at position 371, each relative to amino acid sequence as set forth in SEQ ID NO:
- 4, provided that the RSV F protein has less than 98% sequence identity to SEQ ID NO:
- 4;
- and wherein the RSV F protein has more than 90% sequence identity to SEQ ID NO:
- 1.
A respiratory syncytial virus (RSV) F protein comprising K at position 357 and Y at position 371, each relative to amino acid sequence as set forth in SEQ ID NO:
- 4, provided that the RSV F protein has less than 98% sequence identity to SEQ ID NO:
- 4;
- and wherein the RSV F protein has more than 90% sequence identity to SEQ ID NO:
- 13.
Dependencies are inferred from the claim text.